After national lockdown in the effort to defeat the COVID-19 outbreak, the gradual reopening of Italy was accompanied by a series of measures to limit the infection, including extensive epidemiological surveillance by means of antibody testing on selected risk groups.1 The Regional Council of Lombardy Region (Northern Italy), one of the areas most affected by COVID-19 on a global scale, initially authorized DiaSorin as the only provider of SARS-CoV-2 serologic test for diagnostic and epidemiological purposes. The use of a single test allowed comparisons among results and the harmonization of epidemiological data, but it caused delays in the kit supply and lack of instrument access, limiting further implementation of epidemiological surveillance on a large scale.  

While serologic tests lack of sensitivity as diagnostic test (IgG antibodies appears after symptom onset, thus they are not sensitive in the period when the risk of transmission is higher), they are particularly valuable for purposes other than the diagnostic as they allow to assess the infection burden, to outline the transmission rate in certain settings, and to evaluate the effectiveness of control policies.2  

We evaluated two commercial kits designed to detect SARS-CoV-2 IgG: Diasorin LIAISON®SARS-CoV-2  IgG (chemiluminescent assay, CLIA, Diasorin, Italy)3 and Euroimmun Anti-SARS-CoV-2 ELISA IgG (enzyme-linked immunosorbent assay, Lubeck, Germany)4 in the sero-epidemiological screening of healthcare workers (HCWs) in a tertiary children’s hospital in Milan. Both tests received CE approval... Accedi per continuare la lettura